Summary: A new study from Auburn University reports that the experimental drug troriluzole can prevent early brain changes associated with Alzheimer’s disease in a mouse model. The research shows that troriluzole lowers excessive synaptic glutamate, reduces brain hyperactivity, and preserves memory and learning—findings that support further exploration of glutamate-modulating therapies for early-stage Alzheimer’s.
This discovery suggests that intervening early with a drug like troriluzole could slow or possibly halt progression of Alzheimer’s-related cognitive decline. While the results in 3xTg-AD mice are promising, additional research is required to determine safety, dosing, and effectiveness at different stages of the disease and in humans.
Key Facts:
- Troriluzole reduces synaptic glutamate levels, which helps protect neural function in early Alzheimer’s models.
- Mice treated with troriluzole showed improved performance on memory and learning tasks compared with untreated animals.
- Further studies are necessary to assess troriluzole’s effects across disease stages and to evaluate translational potential for patients.
Source: Auburn University
Auburn University researchers report that troriluzole prevents early synaptic and cognitive changes in an Alzheimer’s mouse model.
Published in the Journal of Neurochemistry, the study led by Dr. Miranda Reed (Department of Drug Discovery and Delivery) and Dr. Michael Gramlich (Assistant Professor of Biophysics) is the first to demonstrate that troriluzole directly targets presynaptic glutamatergic dysfunction that appears during early Alzheimer’s disease. The team’s experiments suggest that modulating glutamate release can protect synapses and preserve cognitive function before major neuronal loss occurs.
“By studying how drug treatments can intervene early in the disease process, we aim to develop therapies that might prevent or delay Alzheimer’s,” said Dr. Reed. Dr. Gramlich added that the collaborative work bridges basic neuroscience and pharmacology to address a fundamental mechanism of early Alzheimer’s pathology.
Understanding the problem: glutamate, synapses, and early Alzheimer’s
Alzheimer’s disease leads to progressive memory loss, cognitive decline, and eventually loss of independence for millions worldwide. Classic hallmarks include amyloid-beta plaques and tau tangles that disrupt neuronal networks. In the earliest stages, excessive glutamate release and resulting synaptic hyperactivity have been linked to synapse dysfunction and cognitive symptoms. Presynaptic changes—such as alterations to synaptic vesicle pools and glutamate transporters—appear to drive this early hyperactivity and are emerging as potential therapeutic targets.
Study design and main findings
The researchers used the 3xTg-AD mouse model, which develops both amyloid and tau pathology, to explore presynaptic glutamatergic alterations and to test the effects of troriluzole. In hippocampal cultures from these mice, the team observed increased presynaptic vesicular glutamate transporter (VGlut1) expression and elevated glutamate release—consistent with enhanced excitatory signaling. The 3xTg cultures also showed an expanded synaptic vesicle pool, a feature attributed to amyloid-related changes.
When 8-month-old 3xTg mice received troriluzole, investigators measured a clear reduction in VGlut1 expression, lower basal and evoked glutamate release, and decreased neural hyperactivity. Behaviorally, treated mice performed better on memory tasks, including maze navigation, indicating preservation of cognitive function.
Troriluzole is a third-generation tripeptide prodrug of riluzole designed to modulate glutamatergic signaling. In this study, its action at presynaptic sites appears to normalize excitatory neurotransmission, preventing downstream synaptic and cognitive impairments that typically follow early glutamatergic dysfunction.
Collaborative effort and implications for neuropharmacology
This work was a multidisciplinary collaboration across Auburn University’s College of Science and Mathematics, the Harrison College of Pharmacy, the Center for Neuroscience Initiative, and participating students and private researchers. The team highlights how combining pharmacology and neuroscience can reveal actionable mechanisms and identify candidate therapies for neurodegenerative disease.
While animal model results cannot be directly extrapolated to humans, these findings reinforce the idea that early intervention targeting glutamate dysregulation may be a promising strategy for slowing Alzheimer’s progression. The authors call for additional preclinical studies to define optimal dosing windows, long-term outcomes, and potential translation to clinical trials.
About this neuropharmacology and Alzheimer’s disease research news
Author: Mary Prater
Source: Auburn University
Contact: Mary Prater – Auburn University
Image credit: Neuroscience News
Original Research: Closed access. “Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg-AD mice” by Michael Gramlich et al., Journal of Neurochemistry.
Abstract (concise)
In Alzheimer’s, early-stage pathology is linked to excessive glutamatergic synaptic activity and presynaptic dysfunction. Using the 3xTg-AD model, this study found increased presynaptic VGlut1, elevated glutamate release, and an expanded synaptic vesicle pool. Treatment with the glutamate-modulating prodrug troriluzole reduced VGlut1 expression, lowered basal and evoked glutamate release, and reversed memory and synaptic deficits in treated mice. These results suggest presynaptic glutamatergic alterations are early, targetable events in Alzheimer’s and support continued investigation of glutamate-modulating therapies such as troriluzole.